Portugal

Credo Diagnostics Biomedical And A. Menarini Diagnostics Sign An Exclusive Distribution Agreement For Sars-cov-2 Assay On The Vitapcrtm Platform


Florence, Italy and Singapore, April 2nd, 2020 – Credo Diagnostics Biomedical Pte. Ltd. and A. Menarini Diagnostics announced today they have entered into an exclusive long-term strategic distribution partnership.

Under this agreement, Menarini will immediately begin the distribution of SARS-CoV-2 assay and other respiratory assays, which includes Influenza A&B, Influenza A&B + Respiratory Syncytial Virus (RSV) panel, and group A Streptococcus (group A strep).

The tests will run on Credo Diagnostics Biomedical's VitaPCRtm platform, a CE marked, state-of-art, rapid Point-of-Care molecular test. This revolutionary test allows the detection of SARS-CoV-2 in 20 minutes. With minimal training and no additional equipment needed, the test can be deployed anywhere from laboratories to decentralised settings and other high-risk locations.

The real-time management of patients undergoing an evaluation at healthcare facilities, which results in a streamlined clinical workflow, is one of the utmost challenges faced by modern Healthcare systems across the world. As such, the VitaPCRtm platform is designed to make an impact at point of need, being an extremely fast and efficient solution to meet the requirement of an early and accurate diagnosis.

Introduced by Credo Diagnostics Biomedical at last year’s American Association of Clinical Chemistry (AACC) Exhibition, the VitaPCRtm is a real-time PCR Point-of-Care versatile platform, combining speed with ease-of-use while delivering laboratory-like accurate results.

With its large and capillary network in the European market, Menarini will be able to scale up the availability of tests for this pandemic, managing the distribution of the platform throughout Germany, Italy, United Kingdom, Spain, Portugal, Netherlands, Sweden, Denmark, Austria and Greece.

"We have always believed that Point-of-Care molecular testing is the future. We look forward to working with Menarini Diagnostics to bring these tests to the market, especially in a crisis like this to save lives" said Dr. Winston Wong Jr., Chairman of Credo Diagnostics Biomedical.

“We relentlessly worked at Menarini Diagnostics to support healthcare professionals in this unprecedented virus outbreak, knowing that speed and convenience of diagnostic tools at point of need can save lives and contain the pandemic .” said Fabio Piazzalunga, General Manager of A. Menarini Diagnostics and President of Menarini Silicon Biosystems.

“It is extremely important in these days scenario, to have solutions that allow the detection of positive cases minimizing time and logistics, bringing the screening where it is needed and run it in the quickest fashion with the most accurate technology possible. We are starting such a collaboration with Credo Diagnostics Biomedical knowing that through it, Menarini Diagnostics will be able to give a significant help to our countries in a time when it is needed the most. We are here to serve, close to healthcare professionals and patients in these difficult days”

About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Animal Health, Human Health, and Human Wellness. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides the most advanced medical technologies for all. For further information, please visit www.credodxbiomed.com

About A.Menarini Diagnostics srl
A.Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, meeting and exceeding the technological needs of Europe's most prominent healthcare professionals, improving and enhancing the quality of life of people all over the world.

A. Menarini Diagnostics belongs to the Menarini Pharmaceutical Group, which was founded in 1886. Today it is present in 136 countries throughout the world, it counts more than 17,000 employees and has a 2018 turnover of € 3.667 billion. For further information, please visit www.menarinidiagnostics.com
A.Menarini Diagnostics S.r.l. Via dei Sette Santi, 3 Florence Italy

Our Values

10 core values have influenced the progress of our group.

READ MORE »